Orforglipron

Orforglipron works by mimicking the hormone GLP-1, which is involved in the body's regulation of gastric emptying, satiety and blood sugar. This medicine activates the GLP-1 receptor to help reduce feelings of hunger, promote an earlier feeling of fullness and lower food intake. Research suggests that this may lead to weight loss and improved glucose levels. As the medicine is still in development, the exact effects, dosages and long-term results have not yet been established.

As with other GLP-1 agonists, the most common side effects primarily affect the gastrointestinal system. This list of side effects may be updated, as the medicine is still under investigation. The side effects reported to date include:

• Nausea and vomiting
• Constipation
• Diarrhoea
• Indigestion (dyspepsia)

Initial clinical trials show that orforglipron has promising results. In a phase 2 trial, the manufacturer Eli Lilly reported an average weight loss of 12% at the highest dosage.

These are positive results, but further research is needed—including larger phase 3 trials—to definitively establish its safety, efficacy and optimal dosage. As soon as more is known, we will keep you updated.

• Orforglipron is not yet approved in Europe.
• At present, it is unclear when it will be approved or made available.
• As soon as this changes, we will publish the latest information here.

Although orforglipron is not yet available, there are already several proven treatments for people with overweight or obesity, including:

• Saxenda
• Wegovy
• Mounjaro
• Orlistat
• Mysimba
• Xenical

What to Know About Orforglipron Oral GLP-1 | Eli Lilly and Company

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment - PubMed